INSM
$136.00-8.00 (-5.56%)
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Recent News
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
How Insmed (INSM) Is Rewriting Its Story Around Brinsupri And 2026 Expectations
Insmed’s fair value estimate has been fine tuned, with the modeled price target edging from US$212.53 to US$213.00, signaling only a very modest shift in the equity story. That small adjustment lines up with recent Street commentary, where analysts are broadly constructive on Brinsupri and bronchiectasis, yet are carefully updating targets while keeping an eye on execution and sector risks. As you read on, you will see how to track these incremental changes and what they may mean for Insmed’s...
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Brensocatib Approval Gives Insmed New Growth Pillar And Valuation Gap
Insmed's Brensocatib has received its first approval as a treatment for non cystic fibrosis bronchiectasis. The product launch has led to significant initial sales, signaling early commercial traction. This marks the first approved therapy for this condition, addressing an area of unmet medical need. For Insmed, listed as NasdaqGS:INSM, the approval of Brensocatib comes at a time when the share price is $144.0. The stock has seen a 3.2% return over the past week and is up 82.8% over the...